Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 45 (1) , 1-3
- https://doi.org/10.1097/qai.0b013e318046ea31
Abstract
The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.Keywords
This publication has 8 references indexed in Scilit:
- Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort StudyClinical Infectious Diseases, 2006
- Editorial Commentary:Genetic Screening to Prevent Abacavir Hypersensitivity Reaction: Are We There Yet?Clinical Infectious Diseases, 2006
- Clinical and immunogenetic correlates of abacavir hypersensitivityAIDS, 2005
- HLA‐B*5701 typing by sequence‐specific amplification: validation and comparison with sequence‐based typingTissue Antigens, 2005
- Predisposition to abacavir hypersensitivity conferred byHLA-B*5701and a haplotypicHsp70-HomvariantProceedings of the National Academy of Sciences, 2004
- Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsPharmacogenomics, 2004
- Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirPublished by Elsevier ,2002
- Genetic variations in HLA-B region and hypersensitivity reactions to abacavirThe Lancet, 2002